Sign in to view content

Updated Safety and Efficacy Results From the Archway Phase 3 Trial of the Port Delivery System With Ranibizumab (PDS) for Neovascular AMD

Carl C. Awh, MD, FASRS

Video
Published 2021

Related

Percentage of Patients Maintained on Quarterly Anti-VEGF Dosing for the Treatment of Neovascular Age-Related Macular Degeneration Across Key Clinical Trials
David A. Eichenbaum, MD, FASRS
Annual Meeting Talks
2018
Phase 3 Randomized, Double-Masked Studies of Brolucizumab Versus Aflibercept in nAMD: Expanded Primary and Secondary Outcomes From HAWK/HARRIER
Arshad M. Khanani, MD, MA, FASRS
Annual Meeting Talks
2018
A Real-World Analysis in 49,485 Eyes of Visual Acuity Outcomes and Anti-VEGF Therapy Intensity in Neovascular AMD Patients
David F. Williams, MD, MBA
Annual Meeting Talks
2018

Category: AMD-Neovascular

See more